Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY Study

ConclusionIn clinical practice, PF tafluprost/timolol FC provided statistically and clinically significant IOP reductions in patients with OAG and OHT insufficiently controlled on or intolerant to PGA or beta-receptor blocker monotherapy. The full IOP reduction appeared at week 4 and was maintained over the 6-month study period. Key symptoms of ocular surface health improved.Trial RegistrationEuropean Union electronic Register of Post-Authorisation Studies (EU PAS) register number, EUPAS22204.

http://link.springer.com/10.1007/s12325-020-01239-8

Source: Advances in Therapy - February 17, 2020 Category: Drugs & Pharmacology Source Type: research